Physician profile
Melissa L Quick
NPI 1639497910
$5,209.27
in general payments reported to CMS, 2019-2025
24 companies · $1,351 in 2025
The $1,351 reported for 2025 was more than what 86% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $100 · 2022: $446 · 2023: $1,558 · 2024: $1,754 · 2025: $1,351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,663.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,662.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $752.40 | 2022-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $708.58 | 2022-2025 | Caplyta |
| Abbvie INC. | $593.30 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $502.19 | 2021-2024 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $442.80 | 2022-2025 | Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $299.79 | 2023-2025 | Rexulti, Abilify Maintena |
| Alkermes, INC. | $298.35 | 2022-2025 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $266.09 | 2022-2025 | Auvelity, Sunosi |
| Teva Pharmaceuticals USA, INC. | $246.53 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Vanda Pharmaceuticals INC. | $162.74 | 2022-2024 | Hetlioz, Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $144.29 | 2023-2025 | Trintellix |
| Neurocrine Biosciences, INC. | $129.11 | 2023-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $114.05 | 2024-2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $100.89 | 2023-2024 | Quviviq |
| Harmony Biosciences LLC | $76.83 | 2023 | Wakix |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $76.58 | 2024-2025 | Xelstrym, Secuado |
| Ironshore Pharmaceuticals INC. | $75.26 | 2024 | |
| Corium, LLC | $61.94 | 2022-2024 | Azstarys |
| Merck Sharp & Dohme LLC | $41.86 | 2022-2023 | Belsomra |
| Collegium Pharmaceutical, INC. | $37.69 | 2025 | Jornay Pm |
| Sunovion Pharmaceuticals INC. | $29.35 | 2022 | |
| Biogen, INC. | $20.23 | 2025 | Zurzuvae |
| Almatica Pharma LLC | $16.67 | 2023 | Loreev Xr, Sertraline Hcl |
| Jazz Pharmaceuticals INC. | $11.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Quick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.